# Emile Voest

Source: https://onco.cc/people/emile-voest/  
OnCo record `emile-voest` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the DRUP trial giving off-label targeted drugs by genomic match, and developed organoid-based testing.

## Summary

Emile Voest is a medical oncologist and group leader at the Netherlands Cancer Institute (NKI-AvL). His specialisms are precision oncology, organoids and off-label drug access trials, and he works with patient-derived organoids, whole-genome sequencing and functional ex vivo drug testing. He founded the Dutch DRUP trial, which gives off-label targeted drugs by genomic match, and the Hartwig Medical Foundation whole-genome sequencing programme. His Nature paper on the Drug Rediscovery protocol described how this approach expands the use of existing anticancer drugs. He also developed patient-derived organoid co-cultures to test how tumours respond to immunotherapy. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Medical Oncologist and Group Leader, Netherlands Cancer Institute
- Specialisms: Precision oncology; Organoids; Off-label drug access trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Voest%20EE%5BAuthor%5D%20DRUP

## Connected records

- technologies: [Functional (ex vivo) drug testing](https://onco.cc/technologies/functional-drug-testing/), [Patient-derived organoids](https://onco.cc/technologies/organoids/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- institutions: [KWF Dutch Cancer Society](https://onco.cc/institutions/kwf/), [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/)
- key papers: [NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients](https://onco.cc/key-papers/paper-niche-2-nejm-2024/)

---
JSON: https://onco.cc/api/v1/entities/emile-voest.json